# Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis

> **NCT05252754** · PHASE3 · RECRUITING · sponsor: **Johns Hopkins University** · enrollment: 4874 (estimated)

## Conditions studied

- Post-ERCP Acute Pancreatitis

## Interventions

- **DRUG:** Tacrolimus capsule
- **DRUG:** Placebo
- **DRUG:** Rectal Indomethacin

## Key facts

- **NCT ID:** NCT05252754
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-18
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 4874 (ESTIMATED)
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05252754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05252754, "Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05252754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*